Plus deals involving BiomX/Adapative Phage, One/NEX-I, Shionogi/FunPep, Taiho/Haihe, Kinnate/Pierre Fabre, StemCell Technologies/SQZ and more, as well as tech transfer agreements.

The first gene editing medicine and gene therapy for sickle cell disease were approved as the ASH meeting got under way, but novel oral drugs may be key to making treatment more accessible.

The recent ASH meeting began with US FDA approvals of the first genetic medicines for sickle cell disease, but doctors and biopharma companies still see a need for new oral therapies and other options. 

Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.